Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

20.99 -0.36 (-1.69%)
Official Closing Price Updated: 7:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,043,719
Open 21.44
Bid (Size) 20.68 (2)
Ask (Size) 21.24 (1)
Prev. Close 21.35
Today's Range 20.90 - 21.47
52wk Range 10.84 - 24.08
Shares Outstanding N/A
Dividend Yield 5.34%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga

Performance

YTD
+42.69%
+42.69%
1 Month
+13.34%
+13.34%
3 Month
+13.15%
+13.15%
6 Month
+84.77%
+84.77%
1 Year
+4.32%
+4.32%

More News

Read More
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Thursday Is Your Last Chance To Buy Organon Before The Dividend Payout
Via Benzinga
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Beats On Q1, Women's Health Leads the Charge
Via Benzinga
OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Via InvestorPlace
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
Via InvestorPlace
5 Value Stocks In The Healthcare Sector
Via Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
Via Investor's Business Daily
Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
Via InvestorPlace
New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety
Via Benzinga
Exposures Product Safety
Don't Overlook These Low-Risk High-Dividend Yielding Stocks
Via Talk Markets
Topics Stocks
Exposures US Equities
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Via Benzinga
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
From Organon & Co.
Via Business Wire
Why Is Women Health-Focused Organon Stock Trading Higher On Thursday?
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
From Organon & Co.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.